NiKang Therapeutics
Sarah Darmody Wheeler, BS, CCRA has extensive experience in the clinical operations field. Sarah began their career in 2002 as a CRA at Protein Design Labs, Inc. Sarah then moved to Neurocrine Biosciences in 2005 as a Sr. CRA. In 2008, they joined Halozyme Therapeutics, Inc. as a Sr. CRA. In 2011, they returned to Neurocrine Biosciences as a Clinical Trial Manager. In 2012, they began working at Allergan as a Medical Affairs Study Manager. In 2015, they joined Isis Pharmaceuticals as an Assistant Director of Clinical Operations. In 2017, they moved to eFFECTOR Therapeutics, Inc. as a Director of Clinical Operations. In 2019, they joined Turning Point Therapeutics as a Director of Clinical Operations. Most recently, in 2021, they began working at NiKang Therapeutics Inc. as a Senior Director of Clinical Operations.
Sarah Darmody Wheeler, BS, CCRA obtained a Certificate in Clinical Trials Design and Management from the University of California, Santa Cruz in 2004. Sarah received a BS in Health Science from San Diego State University in 1998. Sarah also attended San Diego State University, but did not obtain a degree. Sarah holds a CCRA certification.
This person is not in any offices
NiKang Therapeutics
NiKang Therapeutics, Inc. is a privately-held biotech company focused on developing novel small molecule oncology drug discovery. Their mission is to discover and develop first-in-class, and/or best-in-class small molecule targeted therapies and immuno-oncology (I-O) drugs to help cure cancers.